|
Volumn 9, Issue 8, 2001, Pages 364-365
|
Protein conjugate vaccines - How much is enough? [1]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBODY;
BACTERIAL ANTIGEN;
BACTERIUM ANTIBODY;
HAEMOPHILUS INFLUENZAE TYPE B VACCINE;
MEASLES VACCINE;
MENINGOCOCCUS VACCINE;
PERTUSSIS VACCINE;
PNEUMOCOCCUS POLYSACCHARIDE;
PNEUMOCOCCUS VACCINE;
POLYRIBOSYLRIBITYL PHOSPHATE ANTIBODY;
PROTEIN CONJUGATE VACCINE;
UNCLASSIFIED DRUG;
VACCINE;
AGE;
ANTIBODY RESPONSE;
BACTERIAL INFECTION;
DISEASE CONTROL;
DRUG ACTIVITY;
DRUG COST;
DRUG EFFICACY;
DRUG SAFETY;
GEOGRAPHIC DISTRIBUTION;
HAEMOPHILUS INFLUENZAE TYPE B;
HUMAN;
IMMUNE SYSTEM;
IMMUNOLOGICAL MEMORY;
LETTER;
MEASLES;
MORBIDITY;
MORTALITY;
NASOPHARYNX;
NEISSERIA MENINGITIDIS;
NONHUMAN;
OTITIS MEDIA;
PERTUSSIS;
PRIORITY JOURNAL;
SEROTYPE;
STREPTOCOCCUS INFECTION;
STREPTOCOCCUS PNEUMONIAE;
TREATMENT OUTCOME;
VACCINATION;
|
EID: 0035423160
PISSN: 0966842X
EISSN: None
Source Type: Journal
DOI: 10.1016/s0966-842x(01)02076-5 Document Type: Letter |
Times cited : (5)
|
References (15)
|